PDCD1 and non-small cell lung carcinoma: In summary, the current study suggests that NSCLC with BrMs could obtain barely satisfactory treatment benefit from anti-PD-1/PD-L1 monotherapy, partly due to the specific immunosuppressive TIME of BrMs.